WO2000025765A3 - Wässrige arzneimittelformulierung zur oralen applikation - Google Patents

Wässrige arzneimittelformulierung zur oralen applikation Download PDF

Info

Publication number
WO2000025765A3
WO2000025765A3 PCT/EP1999/007891 EP9907891W WO0025765A3 WO 2000025765 A3 WO2000025765 A3 WO 2000025765A3 EP 9907891 W EP9907891 W EP 9907891W WO 0025765 A3 WO0025765 A3 WO 0025765A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral application
drug formulation
aqueous drug
formulation
quinolone
Prior art date
Application number
PCT/EP1999/007891
Other languages
English (en)
French (fr)
Other versions
WO2000025765A2 (de
Inventor
Tobias Laich
Annette Simon
Hans-Martin Siefert
Original Assignee
Bayer Ag
Tobias Laich
Annette Simon
Siefert Hans Martin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Tobias Laich, Annette Simon, Siefert Hans Martin filed Critical Bayer Ag
Priority to AU64736/99A priority Critical patent/AU6473699A/en
Publication of WO2000025765A2 publication Critical patent/WO2000025765A2/de
Publication of WO2000025765A3 publication Critical patent/WO2000025765A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Die vorliegende Erfindung betrifft eine wäßrige pharmazeutische Zusammensetzung zur oralen Anwendung, die einen Wirkstoff aus der Klasse der Chinolon- oder Naphthyridoncarbonsäure-Antibiotika sowie mindestens eine quellbare Polycarbonsäure oder ein Salz davon umfaßt, ein Verfahren zu ihrer Herstellung sowie die Verwendung derselben zur Herstellung eines Arzneimittels.
PCT/EP1999/007891 1998-10-30 1999-10-19 Wässrige arzneimittelformulierung zur oralen applikation WO2000025765A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64736/99A AU6473699A (en) 1998-10-30 1999-10-19 Aqueous drug formulation for oral application

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19850069 1998-10-30
DE19850069.6 1998-10-30

Publications (2)

Publication Number Publication Date
WO2000025765A2 WO2000025765A2 (de) 2000-05-11
WO2000025765A3 true WO2000025765A3 (de) 2000-08-03

Family

ID=7886163

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/007891 WO2000025765A2 (de) 1998-10-30 1999-10-19 Wässrige arzneimittelformulierung zur oralen applikation

Country Status (3)

Country Link
AU (1) AU6473699A (de)
HN (1) HN1999000174A (de)
WO (1) WO2000025765A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19937115A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
DK1411899T3 (da) * 2001-08-01 2009-06-02 Novartis Ag Smagsmaskerende sammensætning
AU2010247141A1 (en) 2009-05-15 2011-12-15 Redx Pharma Plc Redox drug derivatives
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5152986A (en) * 1987-06-13 1992-10-06 Bayer Aktiengesellschaft Preparation and use of ion exchange resins loaded with quinolonecarboxylic acid derivatives
WO1993017664A1 (en) * 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
EP0614659A2 (de) * 1993-03-11 1994-09-14 Taro Pharmaceutical Industries Limited Arzneimittel in halbfester Form und eine Vorrichtung zu deren Verabreichung
EP0689832A2 (de) * 1994-06-29 1996-01-03 Laboratorios S.A.L.V.A.T., S.A. Antibiotische Zubereitung zur auralen Anwendung
WO1999062498A1 (en) * 1998-06-03 1999-12-09 Taro Pharmaceutical Industries Ltd. Spill resistant pharmaceutical compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5152986A (en) * 1987-06-13 1992-10-06 Bayer Aktiengesellschaft Preparation and use of ion exchange resins loaded with quinolonecarboxylic acid derivatives
WO1993017664A1 (en) * 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
EP0614659A2 (de) * 1993-03-11 1994-09-14 Taro Pharmaceutical Industries Limited Arzneimittel in halbfester Form und eine Vorrichtung zu deren Verabreichung
EP0689832A2 (de) * 1994-06-29 1996-01-03 Laboratorios S.A.L.V.A.T., S.A. Antibiotische Zubereitung zur auralen Anwendung
WO1999062498A1 (en) * 1998-06-03 1999-12-09 Taro Pharmaceutical Industries Ltd. Spill resistant pharmaceutical compositions

Also Published As

Publication number Publication date
AU6473699A (en) 2000-05-22
HN1999000174A (es) 1999-10-13
WO2000025765A2 (de) 2000-05-11

Similar Documents

Publication Publication Date Title
CA2445276A1 (en) Aripiprazole oral solution
CA2297832A1 (en) Pellet-type formulation intended for treating the intestinal tract
AU2001278771A1 (en) Carboxylic acid derivatives, process for producing the same and drugs containingthe same as the active ingredient
TR199500825A2 (tr) Cok üniteli farmasötik müstahzar.
HUP0200895A3 (en) Benzimidazole derivatives of alpha-substituted carboxylic acids, pharmaceutical compositions containing them and their use
IL160253A0 (en) Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
HK1047575A1 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containingthe same.
CA2386690A1 (en) Pharmaceutical tramadol salts
BG108516A (en) Pharmaceutical formulation
WO2001041742A3 (en) Antiviral medication
CA2338794A1 (en) New oral formulation for 5-ht4 agonists or antagonists
AU6827800A (en) Aqueous pharmaceutical composition containing moxifloxacin or salts thereof
AU5647199A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
MY134340A (en) Pharmaceutical formulation having a masked taste and method for the production thereof
AU2001234107A1 (en) Benzoic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
WO2000025765A3 (de) Wässrige arzneimittelformulierung zur oralen applikation
AU5443499A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
CA2380757A1 (en) Pharmaceutical agent comprising a benzamide derivative as active ingredient
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
WO2004058303A3 (en) Compositions of benzoquinolizine carboxylic acid antibiotic drugs
WO2004075828A3 (en) Pharmaceutical composition of alendronic acid, salts or esters thereof, and a process for its preparation
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
AU2002325614A1 (en) Compounds containing lactic acid elements, method for the production and use thereof as pharmaceutically active substances
EP1143990A3 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 64736

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase